<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983671</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-2-080</org_study_id>
    <secondary_id>NL25969.068.09</secondary_id>
    <nct_id>NCT00983671</nct_id>
  </id_info>
  <brief_title>Standardisation of Measurements in Exhaled Breath and Exhaled Breath Condensate.</brief_title>
  <official_title>Optimising and Standardising Measurements of Inflammatory Markers in Exhaled Breath (EB) and Exhaled Breath Condensate (EBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: in various pediatric pulmonary diseases such as asthma, cystic fibrosis or&#xD;
      bronchopulmonary dysplasia an increased inflammation is present. Measuring this inflammation&#xD;
      is often hardly possible and requires invasive techniques such as bronchoscopy.&#xD;
&#xD;
      With the use of exhaled breath condensate (EBC) or exhaled breath (EB) analysis it is&#xD;
      possible to measure the inflammation in an non-invasive way. However, there is a great need&#xD;
      to further standardise these measurements and to identify possible confounding factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Measurement of inflammatory markers (IM) in exhaled breath and exhaled breath condensate&#xD;
      (EB(C)) is a very interesting and useful non-invasive new technique to evaluate airway&#xD;
      inflammation. This technique is helpful for diagnostic and monitoring purposes in both&#xD;
      children and adults with chronic lung disease. The hypothesis of the present study is that&#xD;
      standardisation not only increase the reproducibility of measurements but will also enlarge&#xD;
      the possibility to detect differences between healthy and diseased subjects.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
        1. to investigate the influence of various factors on the concentration of markers in&#xD;
           EB(C); parameters on a subject level (e.g. breathing pattern, nose clip, inspiratory&#xD;
           filter, saliva contamination, physical exertion), on an apparatus level (cleaning&#xD;
           procedures, temperature of the condenser tube, environmental conditions, buffer bags),&#xD;
           and on a measurement/analysis level (sampling time, storage time, storage temperature,&#xD;
           protein inhibitor or bovine serum albumine) can be discriminated.&#xD;
&#xD;
        2. to assess whether the reproducibility of measurements in EB(C) can be increased by&#xD;
           analysing with ellipsometry, lyophilization or by standardising for exhaled volume,&#xD;
           sampling time, or dilution factor.&#xD;
&#xD;
        3. to investigate whether differences in inflammatory markers (IM) in EBC between healthy&#xD;
           and diseased subjects will increase by specific EB(C) sampling from more distal airways.&#xD;
           Children with asthma, cystic fibrosis (CF), primary ciliary dyskinesia (PCD),&#xD;
           bronchopulmonary dysplasia (BPD), and lower respiratory tract infections (LRTI) will be&#xD;
           included.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Part I: Cross-sectional study assessing the random influence of presence or absence of&#xD;
      various factors on the concentration of IM in EB(C); Part II: A short-term prospective study&#xD;
      on reproducibility during five consecutive days; Part III: A cross-sectional comparative&#xD;
      study in several groups of children (healthy, asthma, CF, PCD, BPD, LRTI);&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Study part I and II are performed in healthy adult volunteers. Study part III is performed in&#xD;
      healthy children and in children with asthma, CF, PCD, BPD, and LRTI aged 2-16 years.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      Study part I: Concentration of IM in EB(C). Study part II: Reproducibility as assessed by&#xD;
      coefficients of variations of IM in EB(C).&#xD;
&#xD;
      Study part III: Concentration of IM in EB(C) from more distal and more proximal airways.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study I: concentration of inflammatory markers in EB(C)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study II: Reproducibility of inflammatory markers in EB(C)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study III: concentration of inflammatory markers in EB(C) of the proximal and distal airways</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Asthma</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Chronic Lung Disease</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>children with asthma</arm_group_label>
    <description>children with diagnosed asthma, age 6-18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cystic fibrosis</arm_group_label>
    <description>children with cystic fibrosis, age 6-18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic lung disease</arm_group_label>
    <description>children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pneumonia</arm_group_label>
    <description>children with clinical signs of pneumonia, age 6-18 years</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled breath condensate. Exhaled breath.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        For study I and II: community sample For study III: healthy children recruited at a primary&#xD;
        school, children with asthma, cystic fibrosis, chronic lung disease or pneumonia, recruited&#xD;
        from the outpatient clinic of pediatric pulmonology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        study part I and II:&#xD;
&#xD;
          -  healthy adults, 18-50 years study part III:&#xD;
&#xD;
          -  healthy children age 6-18 years&#xD;
&#xD;
          -  patients with cystic fibrosis&#xD;
&#xD;
          -  patients with asthma&#xD;
&#xD;
          -  patients with chronic lung disease&#xD;
&#xD;
          -  patients with pneumonia, all age 6-18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Study part I and II:&#xD;
&#xD;
          -  Subjects with a history of atopy or respiratory disease, as indicated by the ISAAC&#xD;
             questionnaire.&#xD;
&#xD;
        Study part III:&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  active smoking&#xD;
&#xD;
          -  heart disease&#xD;
&#xD;
          -  syndromes&#xD;
&#xD;
          -  congenital malformations of the airways&#xD;
&#xD;
          -  inability to perform the measurements&#xD;
&#xD;
          -  for patients with lower respiratory tract infection: oxygen need, asthma or other&#xD;
             chronic lung disease, active or passive smoking, inability to perform the&#xD;
             measurements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Dompeling, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M.D. Ottink, MD</last_name>
    <phone>+31-43-3877248</phone>
    <email>m.ottink@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>E. Dompeling, Phd</last_name>
    <phone>+31-43-3877248</phone>
    <email>edward.dompeling@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Centre, Pediatric Pulmonology</name>
      <address>
        <city>Maastricht</city>
        <state>Po Box 5800</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M.D. Ottink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Drs. M.D. Ottink, Fellow pediatric pulmonology</name_title>
    <organization>Pediatric Pulmonology, dept. of Pediatrics, University Hospital Maastricht</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>chronic lung disease</keyword>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

